SCHEMBL5332821

SCHEMBL5332821

Cc1cc(C)c(NS(=O)(=O)c2cccc3nonc23)c(C)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.68
GFER P55789 1/20 0.68
ALDH1A1 P00352 6/20 0.62
MAPK1 P28482 2/20 0.62
KMT2A Q03164 6/20 0.60
MAPT P10636 2/20 0.56
LMNA P02545 1/20 0.56
GAA P10253 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MEN1 O00255 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TASP1 Q9H6P5 1/20 0.53
ACLY P53396 1/20 0.51
HSPD1 P10809 1/20 0.50
PTPN2 P17706 1/20 0.50
PTPN1 P18031 1/20 0.50
PTPN5 P54829 1/20 0.50
HSPE1 P61604 1/20 0.50
GLA P06280 1/20 0.50
HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6392497 0.83 ALDH1A1 (0.75) POLBGFERALDH1A1MAPK1KMT2A
SCHEMBL6397600 0.81 KMT2A (0.67) POLBGFERALDH1A1MAPK1KMT2A
SCHEMBL5242455 0.80 KMT2A (0.70) POLBGFERALDH1A1MAPK1KMT2A
SCHEMBL6393820 0.80 KMT2A (0.64) POLBGFERALDH1A1MAPK1KMT2A
SCHEMBL5244837 0.79 POLB (0.72) POLBGFERALDH1A1MAPK1KMT2A
SCHEMBL5245166 0.79 KMT2A (0.74) POLBGFERALDH1A1MAPK1KMT2A
SCHEMBL5246130 0.79 ALDH1A1 (0.69) POLBGFERALDH1A1MAPK1KMT2A
SCHEMBL6397592 0.79 KMT2A (0.78) POLBGFERALDH1A1MAPK1KMT2A
SCHEMBL5244085 0.78 RORA (0.51) POLBGFERKMT2AMAPTTASP1
SCHEMBL16002834 0.78 POLB (0.63) POLBGFERALDH1A1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP POLB 2997/4885GFER 2796/4885ALDH1A1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.